{"company":{"id":2820471,"name":"Agendia","domain":"agendia.com","url":"https://alion.io/company/agendia"},"section":"news","answer":"Agendia: 18 headlines on record, 4 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"18"},{"label":"In 90 days","value":"4"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":15},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-10-06","kind":"Blog","title":"Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026","url":"https://agendia.com/agendia-ai-driven-digital-pathology-esmo-2026/"},{"date":"2026-10-05","kind":"Blog","title":"How One Test Changed The Course of My Breast Cancer Journey","url":"https://agendia.com/how-one-test-changed-the-course-of-my-breast-cancer-journey/"},{"date":"2026-09-24","kind":"Blog","title":"Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients","url":"https://agendia.com/largest-real-world-evidence-study-in-early-stage-breast-cancer-flex-surpasses-25000-patients/"},{"date":"2026-08-14","kind":"Blog","title":"What Does a MammaPrint High Risk Result Mean?","url":"https://agendia.com/what-does-mammaprint-high-risk-result-mean/"},{"date":"2026-08-11","kind":"Blog","title":"Cancer Diagnostics Are Expanding As New Approaches Provide a Broader View of Tumor Biology and Disease Progression","url":"https://agendia.com/cancer-diagnostics-are-expanding-as-new-approaches-provide-a-broader-view-of-tumor-biology-and-disease-progression/"},{"date":"2026-07-14","kind":"News","title":"Agendia Announces Definitive Mandatory Swiss Health Insurance Reimbursement for MammaPrint","source":"Insurance News InsuranceNewsNet","url":"https://insurancenewsnet.com/oarticle/agendia-announces-definitive-mandatory-swiss-health-insurance-reimbursement-for-mammaprint"},{"date":"2026-06-30","kind":"Blog","title":"Core Needle Biopsy and Genomic Testing in Breast Cancer","url":"https://agendia.com/core-needle-biopsy-genomic-testing-breast-cancer/"},{"date":"2026-06-25","kind":"Blog","title":"Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer","url":"https://agendia.com/genomic-profiling-with-mammaprint-blueprint-predicts-anthracycline-chemotherapy-benefit-and-guides-personalized-treatment-selection-in-hrher2-early-stage-breast-cancer/"},{"date":"2026-06-23","kind":"Blog","title":"Prediction of Anthracycline Benefit in Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2- Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study","url":"https://agendia.com/anthracycline-benefit-hormone-receptor-mammaprint-flex/"},{"date":"2026-06-08","kind":"Blog","title":"ASCO 2026: Genomics Reveal HRD-Treatment Response Link","url":"https://agendia.com/asco-2026-genomics-reveal-hrd-treatment-response-link/"},{"date":"2026-06-01","kind":"Blog","title":"Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy","url":"https://agendia.com/integration-of-molecular-subtyping-and-immune-profiling-to-predict-pathologic-complete-response-in-her2-breast-cancer-treated-with-neoadjuvant-dual-her2-therapy/"},{"date":"2026-06-01","kind":"Blog","title":"Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers","url":"https://agendia.com/association-of-the-70-gene-assay-and-homologous-recombination-deficiency-in-patients-with-high-risk-2-breast-cancers/"},{"date":"2026-05-01","kind":"News","title":"Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer","source":"YahooFinance","url":"https://finance.yahoo.com/sectors/healthcare/articles/agendia-present-flex-study-data-150100995.html"},{"date":"2024-08-19","kind":"News","title":"Agendia secures CE-IVDR certification for breast cancer tests","source":"YahooFinance","url":"https://finance.yahoo.com/news/agendia-secures-ce-ivdr-certification-101249248.html"},{"date":"2024-05-31","kind":"Press release","title":"Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO","source":"businesswire.com","url":"https://businesswire.com/news/home/20240531337641/en/Agendia-to-Present-New-Data-on-3-Year-Outcome-of-Chemotherapy-Treatment-in-Patients-with-Early-Stage-Breast-Cancer-at-2024-ASCO"}],"story":[{"title":"Won a grant $978k · CORDIS","url":"https://cordis.europa.eu/project/id/635342"},{"title":"Won a grant $4.4M · CORDIS","url":"https://cordis.europa.eu/project/id/672570"}],"as_of":"2026-11-15","cite":"Agendia, News. Alion, Nov 15, 2026. https://alion.io/company/agendia/news","html_url":"https://alion.io/company/agendia/news","json_url":"https://alion.io/company/agendia/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-15T12:12:29Z"}}